Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, Epiciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies

Abstract : Cell surface molecules aberrantly expressed or overexpressed by myeloid leukemic cells represent potential disease-specific therapeutic targets for antibodies. MUC1 is a polymor-phic glycoprotein, the cleavage of which yields two unequal chains: a large extracellular a subunit containing a tandem repeat array bound in a strong noncovalent interaction to a smaller b subunit containing the transmembrane and cytoplasmic domains. Because the a-chain can be released from the cell-bound domains of MUC1, agents directed against the a-chain will not effectively target MUC1 + cells. The MUC1 SEA (a highly conserved protein module so called from its initial identification in a sea urchin sperm protein, in enterokinase, and in agrin) domain formed by the binding of the a and b chains represents a stable structure fixed to the cell surface at all times. DMB-5F3, a partially human-ized murine anti-MUC1 SEA domain monoclonal antibody, was used to examine MUC1 expression in acute myeloid leukemia (AML) and was found to bind acute myelomonocytic and monocytic leukemia (AML-M4 and AML-M5) cell lines. We also examined monocytic neoplasms freshly obtained from patients including chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia, which were found to uniformly express MUC1. CD34 + / lin − /CD38 − or CD38 + presumed leukemic stem cell populations from CD34 + AML and CD34 − CD38 − or CD38 + populations from CD34 − AML were also found to express MUC1, although at low percentages. Based on these studies, we generated an anti-MUC1 immuno-toxin to directly gauge the cytotoxic efficacy of targeting AML-bound MUC1. Using single-chain DMB-5F3 fused to recombinant gelonin toxin, the degree of AML cytotoxicity was found to correlate with MUC1 expression. Our data support the use of an anti−MUC1 SEA module−drug conjugates to selectively target and inhibit MUC1-expressing myelomo-nocytic leukemic cells.
Document type :
Journal articles
Complete list of metadata

Cited literature [41 references]  Display  Hide  Download
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Friday, January 25, 2019 - 11:49:39 AM
Last modification on : Wednesday, April 27, 2022 - 4:41:28 AM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




Thierry Guillaume, Virginie Dehame, Patrice Chevallier, Pierre Peterlin, Alice Garnier, et al.. Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies. Experimental Hematology, Elsevier, 2019, 70, pp.97-108. ⟨10.1016/j.exphem.2018.12.002⟩. ⟨inserm-01994077⟩



Record views